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Abstract
Background: Hepcidin is a major regulator of iron metabolism and plays a key role in anemia of chronic disease, reducing
intestinal iron uptake and release from body iron stores. Hypoxia and chemical stabilizers of the hypoxia-inducible
transcription factor (HIF) have been shown to suppress hepcidin expression. We therefore investigated the role of HIF in
hepcidin regulation.
Methodology/Principal Findings: Hepcidin mRNA was down-regulated in hepatoma cells by chemical HIF stabilizers and
iron chelators, respectively. In contrast, the response to hypoxia was variable. The decrease in hepcidin mRNA was not
reversed by HIF-1a or HIF-2a knock-down or by depletion of the HIF and iron regulatory protein (IRP) target transferrin
receptor 1 (TfR1). However, the response of hepcidin to hypoxia and chemical HIF inducers paralleled the regulation of
transferrin receptor 2 (TfR2), one of the genes critical to hepcidin expression. Hepcidin expression was also markedly and
rapidly decreased by serum deprivation, independent of transferrin-bound iron, and by the phosphatidylinositol 3 (PI3)
kinase inhibitor LY294002, indicating that growth factors are required for hepcidin expression in vitro. Hepcidin promoter
constructs mirrored the response of mRNA levels to interleukin-6 and bone morphogenetic proteins, but not consistently to
hypoxia or HIF stabilizers, and deletion of the putative HIF binding motifs did not alter the response to different hypoxic
stimuli. In mice exposed to carbon monoxide, hypoxia or the chemical HIF inducer N-oxalylglycine, liver hepcidin 1 mRNA
was elevated rather than decreased.
Conclusions/Significance: Taken together, these data indicate that hepcidin is neither a direct target of HIF, nor indirectly
regulated by HIF through induction of TfR1 expression. Hepcidin mRNA expression in vitro is highly sensitive to the
presence of serum factors and PI3 kinase inhibition and parallels TfR2 expression.
Citation: Volke M, Gale DP, Maegdefrau U, Schley G, Klanke B, et al. (2009) Evidence for a Lack of a Direct Transcriptional Suppression of the Iron Regulatory
Peptide Hepcidin by Hypoxia-Inducible Factors. PLoS ONE 4(11): e7875. doi:10.1371/journal.pone.0007875
Editor: Carmine Zoccali, L’ Istituto di Biomedicina ed Immunologia Molecolare, Consiglio Nazionale delle Ricerche, Italy
Received June 23, 2009; Accepted October 21, 2009; Published November 18, 2009
Copyright:  2009 Volke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by Roche Pharma AG, Grenzach-Wyhlen, Germany. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: christina.warnecke@uk-erlangen.de
Introduction
The iron regulatory peptide hepcidin (gene name also: HAMP)i s
a liver-derived acute phase peptide and a key regulator of systemic
iron metabolism [1,2,3,4]. Hepcidin triggers internalization and
degradation of the cellular iron exporter ferroportin in the intestinal
epithelium and cells of the reticuloendothelial system thus reducing
intestinal iron absorption and release of iron from body iron stores
[5,6]. High hepcidin serum levels are thus associated with reduced
availability of iron for the hematopoietic system and an inadequate
hematopoietic response even in the presence of appropriate
erythropoietin (EPO) levels and iron supplementation therapy,
features characteristic of the anemia of chronic disease (ACD).
Therefore, novel therapeutic strategies leading to both increased
serum EPO levels as well as reduced hepcidin expression may offer
clinical benefit in the management of ACD.
Iron overload, infection and inflammatory cytokines are well
recognized as factors leading to increased hepatic hepcidin
expression [3,7,8]. Interleukin-6 (IL-6)-stimulated hepcidin induc-
tion is mediated by a highly conserved STAT3 binding element in
the proximal promoter of the HAMP gene [9,10]. This sequence
motif controls both IL-6-induced, as well as basal, HAMP
promoter activity. However, other signalling pathways also
contribute to hepcidin regulation since IL-6 knock-out mice still
induce hepcidin in response to endotoxin injection [11]. Much
information about the determinants controlling hepcidin expres-
sion was obtained from the genetics of hereditary hemochroma-
tosis [12], which is characterized by insufficient hepcidin levels due
to mutations in the transferrin receptor 2 (TfR2) gene, the
hemochromatosis genes HFE and HFE2 (also designated hemoju-
velin=HJV), or the hepcidin gene itself. HFE2/HJV was shown to
be a co-receptor for bone morphogenetic protein 2 (BMP-2), a
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transcription factors that transactivate the HAMP promoter [13].
Liver-specific SMAD4 (the common downstream mediator for all
TGF-b superfamily ligands) knock-out mice exhibit marked iron
accumulation and fail to increase hepcidin expression in response
to TGF-b1, BMP-4, IL-6 or iron overload, suggesting a common
role for SMAD4 in the manifold pathways of hepcidin regulation
[14]. The conserved region of the HAMP promoter contains
several putative binding sites for SMAD4 and BMP receptor-
activated SMADs [13].
Other transcription factor binding sites suggested to contribute
to basal as well as iron-overload induced hepcidin expression are a
C/EBPa binding element and the upstream stimulatory factor
(USF) binding site/E-box in the proximal promoter [15,16].
Previous studies on hepcidin regulation have reported a
decrease of hepcidin expression in response to hypoxia and
anemia [17]. The heterodimeric hypoxia-inducible transcription
factor (HIF) is the master regulator of the systemic and cellular
adaptation to hypoxia. In the presence of molecular oxygen, the
HIF-a subunit is hydroxylated by specific oxygen-, iron- and 2-
oxoglutarate-dependent prolyl hydroxylases (PHDs), which is
prerequisite for binding of the von Hippel-Lindau (VHL) protein,
the recognition component of an ubiquitin ligase complex that
targets HIF-a for proteasomal degradation. Under hypoxia, HIF-a
is stabilized, translocates to the nucleus and binds as a dimer with
the constitutive b-subunit and transcriptional co-activators to the
hypoxia-responsive elements in the promoters or enhancers of its
target genes (for review, see [18,19,20]). Amongst others, HIF
transactivates enzymes of anaerobic glycolysis, glucose transport-
ers, angiogenic factors and proteins involved in iron metabolism
and erythropoiesis such as transferrin, transferrin receptor 1 and
erythropoietin.
New pharmacological PHD inhibitors, which cause stabilisation
of HIF and increased erythropoietin production, are currently
undergoing clinical trials for the treatment of renal anemia.
Intriguingly, these agents have been shown to suppress serum
hepcidin levels in animal models (Langsetmo, I., et al. (2006) FG-
2216 corrects anemia and improves iron utilization in a rat model
of anemia of chronic disease: comparison to darbepoetin.
Keystone Symposium ‘Hypoxia and Development, Physiology
and Disease’. Breckenridge, CO, USA. pp. abstr. 247.; Seeley, T.,
et al. (2006) FG-2216: Tumor progression studies and correction of
anemia of cancer in xenograft models. Keystone Symposium
‘Hypoxia and Development, Physiology and Disease’. Breck-
enridge, CO, USA. pp. abstr. 328). Furthermore, hepatocyte-
specific HIF-1a knock-out in mice was associated with a markedly
attenuated down-regulation of hepcidin expression under low iron
diet in comparison with wildtype mice [21]. Stimulated by these
studies we investigated the mechanisms underlying hypoxic
hepcidin regulation and asked whether HIF is involved in
hepcidin suppression. Our results show that hepcidin suppression
is neither directly mediated by HIF nor indirectly through
induction of transferrin receptor 1 (TfR1). Hepcidin expression
in vitro strongly depends on serum factors and parallels TfR2
expression.
Methods
Cell Culture
Human hepatoma HepG2 cells were purchased from the
German Collection of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany). Human hepatoma Huh7 cells were a
kind gift from Prof. Martina Muckenthaler, University of
Heidelberg, Germany. Cell culture media and reagents were from
PAA Laboratories (Coelbe, Germany). HepG2 and Huh7 cells
were grown in Dulbecco’s modified eagle medium with 1.0 g
respectively 4.5 g glucose/l, 10% fetal calf serum (FCS), 2 mM L-
glutamine, 100 U penicillin and 100 mg streptomycin per ml, and
maintained at 37uC in a humidified 5% CO2 incubator.
Stimulation Protocols
Cells were exposed to hypoxia (1% O2,5 %C O 2, 94% N2)i na
HeraCell 150 hypoxic incubator (Thermo Electron) or stimulated
with the iron chelator and HIF stabilizer 2,29dipyridyl (DP,
100 mM; ICN Biomedicals, Irvine, CA, USA), the iron-indepen-
dent hydroxylase inhibitor and HIF stabilizer dimethyloxalylgly-
cine (DMOG, 1 mM; Frontiers Scientific Europe, Carnforth,
Lancashire, U.K.) or the iron chelator desferrioxamine (DFO,
100 mM; Sigma-Aldrich, St. Louis, MO, USA) for 16 h–18 h if
not indicated otherwise. IL-6 (2–10 ng/ml) and BMP-2 (100 ng/
ml) were purchased from Hiss Diagnostics, Freiburg, Germany.
To identify kinase pathways that were driving basal hepcidin
expression in cultured cells in the presence of FCS, the following
inhibitors were used: the phosphatidylinositol 3 kinase (PI3K)
inhibitor LY294002 (10 mM, Calbiochem), the p38 stress-activated
protein kinase (SAPK) inhibitor SB202190 (10 mM, Sigma), the
mitogen-activated protein kinase kinase (MEK)1/2 inhibitor
UO126 (1 mM, Cell Signaling) and the pan kinase inhibitor
staurosporine (0.5 mM, Sigma).
HIF Activation by Hypoxia, Carbon Monoxide or Chemical
HIF Inducers in Mice
Mice livers were obtained from control animals of a study
designed to investigate the protective effects of HIF activation on a
subsequent kidney injury. These animal experiments were
approved by the institutional review board for the care of animal
subjects (Regierung von Mittelfranken, registration no.: 54-
2531.31-25/06) and performed in accordance with National
Institutes of Health guidelines and the German Animal Welfare
Act. Six-weeks-old Balb/c mice (Charles River, Germany) were
fed on a normal diet (‘Altromin 1324’, Altromin, Germany) and
exposed to 8% O2/92% N2 for 8 h or to 8% O2/92% N2 for 8 h
followed by 16 h at 10% O2/90% N2. Alternatively, mice were
treated with 0.1% carbon monoxide in normal air for 6 to 8 h.
Subsequently mice were killed by cervical dislocation and the livers
were removed and immediately snap-frozen in liquid nitrogen. In
an alternative approach, 6-weeks old male C57BL/6 mice were
injected twice with the chemical HIF inducer N-oxalylglycine
(OG, 9.2 mg/animal per injection; Frontiers Scientific Europe,
Carnforth, Lancashire, U.K.) and sacrificed 16 hours after the
second injection (24 h OG +16 h OG). In the second group, mice
were injected with vehicle (tris-buffered saline) 24 hours after the
OG treatment (24 h OG +16 h Tris). Control mice received
vehicle only (24 h Tris +16 h Tris). Liver samples were immedi-
ately snap-frozen on liquid nitrogen and RNA was prepared for
RNase protection assay or quantitative RT PCR as described
below.
RNA Preparation and RNase Protection Assay
Total RNA was prepared from cell cultures and mouse livers
using RNABee
TM (Biozol). Templates for RNA probes for human
HAMP and mouse HAMP-1, human nucleoporin 98, TfR1 and
TfR2 were generated by reverse transcriptase PCR (see Table 1A
for primer sequences). Amplified fragments were cloned into the
pcDNA3 vector (Invitrogen). Probes for U6 small nuclear RNA
(U6sn), IGFBP1 and AngPTL4 were described before [22]. RNase
protection assays were carried out as described previously [22,23].
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(FujiBAS 2000, Fuji) and the AIDA
TM image analysis software
(Raytest).
SiRNA Transfections
Cells were transfected with HIF-1a, HIF-2a or control siRNAs
(luciferase (2 luc, 3 luc) or green fluorescent protein (GFP)) at a
Table 1. Primer sequences.
A. Primers used for cloning of RNase protection assay probes
human HAMP acc. no. NM_021175.2
hHAMP.Kpn+ 59AGCGGTACCAGTGGCTCTGTTTTCCCAC
hHAMP.Xho2 59GTCCTCGAGCACATCCCACACTTTGATCG
mouse HAMP-1 acc. no. NM_032541.1
mHAMP.Kpn+ 59CTCGGTACCCAGGCTGCCTGTCTCCTG
mHAMP.Xho2 59CACCTCGAGCAGAAGATGCAGATGGGGAAG
human nucleoporin 98 acc. no. U41815
NUP98.Kpn+ 59TTTGGTACCAGTTCATTTAGCCAGGC
NUP98.Xho2 59TCCCTCGAGTCCTCCACTGCTAGTACTG
human transferrin receptor 1 acc. no NM_003234
hTfR1.Kpn+ 59GCAGGTACCGAGTCTCCAGTGAGG
hTfR1.Xho2 59CTTCTCGAGATCCAGCCTCACGAGG
human transferrin receptor 2 acc. no. NM_003227
hTfR2.Kpn+ 59ACCGGTACCTGGTCCTGACGGCCCTG
hTfR2.Xho2 59GGCCTCGAGGTCGCTCCAGTAGAGTCTG
B. Primers used for cloning of HAMP promoter constructs
construct HAMP.prom acc. no. NT 011109.15/Hs 1911266
HAMP.prom+ 59TTACTCGAGCCACATCTCAAGGGTCTGAC
HAMP.prom2 59TGCAAGCTTGCCGTCTGTCTGGCTGTCC
construct HAMP.prom.CpG acc. no. NT 011109.15/Hs 1911266
HAMP.CpG+ 59CCTGGTACCGCTGGGGGCTGCTCCTGTGT
HAMP.CpG2 59TGGCTCGAGTAACTGGAAAATGTTTGAGCAAAG
construct HAMP.promDHRE acc. no. NT 011109.15/Hs 1911266
HAMP.promDHRE 59GTGTCTCGAGAGCTTAAAGCAATGGATGC
C. Primers used for quantitative RT PCR
human HAMP Hs_00221783_m1 (Applied Biosystems)
18S RNA Hs_99999901_s1 (Applied Biosystems)
human BMP-2 acc. no. NM_001200
BMP-2+ 59GACACTGAGACGCTGTTCC
BMP-22 59CCATGGTCGACCTTTAGG
human BMP-4 acc. no. NM_130851.2
BMP-4+ 59GCCGGAGGGCCAAGCGTAGCCCTAAG
BMP-42 59CTGCCTGATCTCAGCGGCACCCACATC
human BMP-6 acc. no. NM_001718.4
BMP-6+ 59AAGGCTGGCTGGAATTTGACATCACG
BMP-62 59GGTAGAGCGATTACGACTCTGTTGTC
human HAMP acc. no. NM_021175.2
hHAMP+ 59CCACAACAGACGGGACAACTT
hHAMP2 59GGTTCTACGTCTTGCAGCACA
mouse HAMP-1 acc. no. NM_032541.1
mHAMP-1+ 59CCTATCTCCATCAACAGATG
mHAMP-12 59AACAGATACCACACTGGGAA
mouse HIG2 acc. no. AF141311
mHIG2+ 59ACCGTCGCCATGAAGTTCATGC
mHIG22 59CCTTAGGAGGCTGTGTGTTGG
doi:10.1371/journal.pone.0007875.t001
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TfR1 knock-down three independent siRNAs were used (sense
strands): TfR1_A 59GGAAUAAGGCCUUAAUAUG, TfR1_B
59GGUACAACAGCCAACUGCU, and Hs_TFRC_5 no. SI
00301896 (59AAGUAGAUGGCGAUAACAGUC, Qiagen).
Immunoblotting
Immunoblotting for HIF-1a (rabbit antiserum NB100–449,
Novus Biologicals, USA), HIF-2a (mouse monoclonal antibody
(mab) NB100–132) and transferrin receptor 1 (mab DF1513,
Sigma) was performed as described previously [24]. Immuno-
staining for b-actin (mab AC74, Sigma) or a-tubulin (mab DM1A,
Sigma) served as loading control.
Reverse Transcriptase PCR (RT PCR)
Hepcidin mRNA expression in HepG2 and Huh7 cells was also
quantified by RT PCR. Primers used were commercially available
Taqman primers/probes from Applied Biosystems, or were
designed using the NCBI primer design software. Hepcidin
mRNA levels were related to 18S RNA. Expression analyses of
BMP-2,-4 and -6 in Huh7 and HepG2 cells were performed by
quantitative RT PCR in a LightCycler (Roche) as described before
[25]. All primer sequences are listed in Table 1C.
Cloning of Human HAMP Promoter Reporter Constructs
Three different hepcidin promoter fragments were amplified
from genomic DNA by PCR using the primers given in Table 1B
and Combizyme Polymerase Mix (Invitek), and cloned into the
pGL2basic vector (Promega). The first construct (HAMP.prom)
contained the proximal promoter, including the two putative
HREs, from 2nt 617 up to the translation start codon in the first
exon. For a longer construct (HAMP.prom.CpG) a 1646 bp
fragment containing the CpG island, which is located upstream of
the core promoter, was fused 59 to the 617-bp core promoter. In
the third construct (HAMP.promDHRE) a 145-bp region
spanning the putative HREs was deleted from the core promoter.
All plasmids were controlled by DNA sequencing.
Luciferase Reporter Gene Assays
500 ng of the hepcidin promoter luciferase reporter plasmids
were co-transfected with 50 ng of a pCMV-b-galactosidase
expression vector in HepG2 or Huh7 cells by the use of
Lipofectamine 2000 transfection reagents (Invitrogen). For HIF-
a knock-down, 50 nM siRNAs were co-transfected with the
plasmids as described before [24]. Cells were exposed to hypoxia,
DP, DMOG, IL-6 or BMP-2 for 16 h, and subsequently lysed for
determination of luciferase and b-galactosidase activities (Pro-
mega). Luciferase activities were normalized according to the
respective b-galactosidase activities.
As control for the hypoxic induction a 6xHRE luciferase
plasmid was used, which comprised six copies of the HRE of the
phosphoglycerate kinase gene upstream of a thymidin kinase promoter. In
some experiments a normoxically stable mouse HIF-1a triple
mutant (mHIF-1aTM [24]) was co-transfected with the HAMP
promoter constructs to determine the effect of HIF overexpression
on HAMP promoter activity.
In HIF-a knock-down experiments 3 luc siRNA was used as
negativecontrolforthepGL2-basedHAMPpromoter constructs, and
2 luc siRNA as negative control for the pGL3 6xHRE construct [26].
Analysis of TfR2 Protein Expression
TfR2 expression was determined by flow cytometry in HepG2
cells using the TfR2 mouse monoclonal antibody clone 353816
(R&D Systems).
Statistical Analysis
Data are given as means6standard deviation (SD), if not
indicated otherwise. Data were analysed using Student’s t-test,
Mann Whitney test and one-way ANOVA, as appropriate. A p
value ,0.05 was considered significant.
Results
Regulation of Hepcidin mRNA Expression by Hypoxia and
Chemical HIF Inducers
We first analyzed the response of hepcidin mRNA levels to
hypoxia and chemical HIF stabilization in HepG2 cells. DP and
DFO chelate Fe
2+ and Fe
3+, respectively, and inhibit iron- and 2-
oxoglutarate (2-OG)-dependent dioxygenases, including the HIF
PHDs and the asparagyl hydroxylase factor inhibiting HIF-1 (FIH-
1), which leads to stabilization and activation of HIF even under
normoxia. DMOG inhibits dioxygenases by competition with 2-
OG [27]. While exposure to DP (100 mM) for 16 h robustly and
consistently suppressed hepcidin mRNA levels, the response to
hypoxia (1% O2) was variable and accompanied by an increase in
hepcidin mRNA expression in 13 out of 15 experiments
(Figure 1A). Exposure to DMOG (1 mM) was also associated
with suppression of hepcidin mRNA, although in 3 out of 13
experiments hepcidin mRNA levels were slightly increased
(Figure 1A). Transcription of known HIF target genes such as
IGFBP1 [28,29] and ANGPTL4 [30] were reliably induced by both
hypoxia and chemical HIF stabilization (IGFBP1 in HepG2 cells:
1968.5-fold by DMOG, 22.661.1-fold by DP, 15.365.5-fold by
hypoxia; n=7), verifying that HIF was activated under these
conditions (Figure 1A).
Similar results were obtained in independently designed and
performed experiments in a second laboratory: exposure to DFO
(100 mM) reduced hepcidin mRNA (measured by reverse
transcriptase real time quantitative PCR) to 7.667.1%
(p,0.001, n=8), whereas hypoxia again led to variable effects
on hepcidin transcript expression with no difference in average
transcript levels (103680% of normoxic controls, n=8). We first
hypothesized that the characteristic cluster-like growth of HepG2
cells, which makes cell density difficult to control, may have
confounded regulatory mechanisms. However, in human Huh7
hepatoma cells, which grow in monolayers, hepcidin mRNA
expression was also highly variable under hypoxia, but signifi-
cantly decreased by DMOG and DP, whereas established HIF
target genes were consistently induced by hypoxia and chemical
HIF activation (Figure 1B).
Since chemical HIF stabilizers also inhibit iron- and 2-OG-
dependent dioxygenases other than the HIF PHDs and FIH-1, the
observation that the hepcidin response differed between HIF
activation by hypoxia and by chemical stabilization suggested that
HIF was not the most important determinant of hepcidin
expression in these experiments.
Serum Deprivation Leads to a Marked Decrease of
Hepcidin mRNA Levels
Because consecutively performed experiments tended to show
more similar hepcidin responses than those seen in widely
separated experiments and the batches of the fetal calf serum
(FCS) used for cell culture had been changed during this period,
we investigated whether components of FCS could affect hepcidin
expression. Serum deprivation from 10% to 0.4% rapidly reduced
hepcidin mRNA levels in hepatoma cells. In Huh7 cells hepcidin
transcript levels decreased to 5468% after 2 h and 25615% after
8 h of serum deprivation (p,0.05 vs. controls, n=3; Figure 2A).
After 40 h, hepcidin expression was almost completely eliminated
Hepcidin Is Not a HIF Target
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by phosphoimaging revealed that the effects of DP and DMOG on
hepcidin mRNA expression were maintained in the absence of
serum (0.6560.04-fold by DMOG; 0.4160.38-fold by DP),
whereas the effect of hypoxia was not significant (1.2360.3-fold;
n=4). Addition of transferrin-bound iron up to 2 mg/ml for 16 h
neither prevented the decrease nor caused an increase in hepcidin
levels (data not shown), which suggested that other components of
the FCS were required to maintain basal hepcidin expression and
that variability in the abundance of these factors in different
batches of FCS may have contributed to the variability of hypoxic
hepcidin expression between experiments. To further delineate the
signalling pathways driving basal hepcidin expression in the
presence of serum we used four different kinase inhibitors: the
specific phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002,
which blocks growth factor-stimulated receptor tyrosine kinase
signalling, the protein kinase inhibitor staurosporine, which
inhibits protein kinase C and other kinases, the p38 a and b
stress-activated protein kinase (SAPK) inhibitor SB202190, and
the mitogen-activated protein kinase kinase (MEK)1/2 inhibitor
UO126, which leads to a reduction of ERK1/2 activity and
therefore also blocks signalling pathways of several growth factors.
In Huh7 cells the kinase inhibitor staurosporine and the specific
PI3 kinase inhibitor LY294002 significantly reduced hepcidin
expression after 4 h and 6 h to about 50% and 40%, respectively,
whereas UO126 intriguingly increased hepcidin expression after
2–6 h (Figure 2C). SB202190 had no effect in Huh7 cells. To test
whether the increase by UO126 after 2 h was already caused by a
counter-regulation, we also determined hepcidin mRNA levels
after 30 and 60 min. Hepcidin mRNA increased 1.560.1-fold
after 30 min and 1.860.2-fold after 60 min (n=2, data not
shown) suggesting that the observed effects were indeed direct
effects. In HepG2 cells UO126 had comparable effects (not
shown). These results indicate that PI3 kinase activity is required
for basal hepcidin expression, whereas the MAP kinase pathway
seems to suppress hepcidin expression in hepatoma cells.
HIFs Are Not Necessary for the Modulation of Hepcidin
mRNA Expression In Vitro
The transcriptional response to hypoxia is mediated predom-
inantly by two HIF-a family members, HIF-1a and HIF-2a.T o
determine whether either of these HIF-a subunits is necessary for
the modulation of hepcidin mRNA levels we transfected HepG2
cells with siRNAs directed against HIF-1a or HIF-2a. For each
HIF-a subunit two different siRNAs were used. In no case was the
knock-down of either HIF-a subunit accompanied by a rise in
hepcidin mRNA (Figure 3A). Rather, hepcidin transcript levels
appeared to be further reduced by HIF-1a knock-down (62623%
of luc siRNA-transfected, DMOG-stimulated HepG2 cells,
p,0.05, n=4), whereas HIF-2a siRNA had no significant effect
(86638% of luc siRNA-transfected cells). These results indicate
that neither HIF-a subunit is required for the suppression of
hepcidin by DMOG or DP. Even in those experiments where
hypoxia was accompanied by reduced hepcidin mRNA levels, this
suppression was also not abolished by HIF-a knock-down
(Figure 3A). Moreover, combined knock-down of HIF-1a and
HIF-2a did not have a significant effect on hepcidin expression
(data not shown). Knock-down efficiencies were controlled by
analyses of HIF-a protein expression (Figure 3B) and modulation
of mRNA levels of IGFBP1 and AngPTL4 (Figure 3C), which
were previously shown to be regulated in HepG2 cells by HIF-2a
and HIF-1a, respectively [22]. In addition, down-regulation of
nucleoporin 98 mRNA, a gene identified as a negative target of
HIF-1a in a gene array study [22], was abrogated by HIF-1a
knock-down in HepG2 and Huh7 cells, which demonstrated that
HIF knock-down can also reverse HIF-mediated down-regulation
of gene expression (Figure 3D–E).
The Regulation of Hepcidin mRNA Expression by Hypoxia
and Chemical HIF Activation May Not Be Solely Mediated
by the Promoter Region
To investigate whether the effects of hypoxia and chemical HIF
stabilization on hepcidin mRNA levels are transcriptional, we
analyzed the human hepcidin promoter in silico and in reporter
assays. Using Genomatix MatInspector software [31] we identified
two putative hypoxia-responsive elements (HREs, CACGTG) 511
and 583 bp upstream to the start codon in exon 1, which also
matched the E-box/USF binding site consensus sequence
(CANNTG), and a further putative HRE on the antisense strand
between the two HREs/E-boxes (Figure 4A). We hypothesized
that HIF could act as a competitor at the congruent cis-active
elements and displace positive regulators such as USF and c-myc
under hypoxic conditions although in the murine promoter the
HREs are not identical with these transcription factor binding
sites.
To test our hypothesis, we cloned three fragments of the human
hepcidin promoter in the pGL2basic luciferase vector: the first
comprised a 617-bp core promoter fragment (HAMP.prom). The
second contained, upstream to the core promoter, a 1635-bp
fragment of the adjacent 59flanking region which comprised a
CpG island (HAMP.prom.CpG). The third construct was a
deletion mutant of the core promoter which lacked the region
encompassing the putative HREs (HAMP.promDHRE).
Luciferase reporter assays in HepG2 and Huh7 cells revealed
that the hepcidin promoter responded differently in the two cell
Figure 1. Response of hepcidin transcript levels to hypoxia and
chemical HIF stabilization in human hepatoma cells. (A) RNase
protection assays (RPA) demonstrating hepcidin (HAMP) mRNA
regulation and HIF target gene (IGFBP1 and ANGPTL4) induction in
HepG2 cells after 16 h exposure to hypoxia (1% O2), dimethyloxalylgly-
cine (abbreviated DG or DMOG) or 2,29dipyridyl (DP). (B) Hepcidin
(HAMP), IGFBP1 and ANGPTL4 mRNA regulation in Huh7 cells. U6sn
RNA served as loading control. Quantification was performed by
phosphoimaging. Data are expressed as means6standard deviation
(SD) of the indicated number of experiments; *p,0.05, **p,0.01 vs.
unstimulated controls.
doi:10.1371/journal.pone.0007875.g001
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the regulation at the mRNA level for all of the stimuli. Exposure to
hypoxia, DMOG or DP of Huh7 cells transfected with the
HAMP.prom construct resulted in the anticipated reduction of
luciferase activity (Figure 4B). In contrast, HepG2 cells
transfected with the HAMP.prom construct showed an increase
in luciferase activity when exposed to DP and no significant
change when exposed to hypoxia or DMOG. Despite these
differences between cell types, the effects of HIF-a knock-down or
removal of the putative HREs in the promoter constructs were
identical: Neither knock-down of the HIF-a subunits nor deletion
of the putative HREs altered the response to DMOG, DP or
hypoxia (Figure 4C–D). Overexpression of a normoxically stable
HIF-1a mutant was associated with mildly increased luciferase
activity. However, this effect was also independent of the presence
of the putative HREs in the HAMP promoter (Figure 4E). A
6xHRE luciferase construct, which is activated by endogenous
HIF-1a, but not HIF-2a, was used as control for these
experiments.
To confirm that the hepatoma cells responded to other known
stimuli as previously reported and that the cloned hepcidin
promoter fragments were functional, we stimulated HepG2 and
Huh7 cells with IL-6 and BMP-2. Exposure to IL-6 for 16 h led to
a significant dose-dependent increase of hepcidin mRNA levels in
both cell lines (Figure 5A–B). We then determined the effects of a
combined exposure to IL-6 and hypoxia or chemical HIF
inducers. The induction by IL-6 may have been attenuated in
HepG2 cells in the presence of DMOG, although this difference
did not reach statistical significance (IL-6 2.760.9-fold, IL-6 plus
DMOG 1.2360.2-fold vs. unstimulated controls; n=3, p=0.056;
Figure 5C). The moderate induction by hypoxia in these
experiments was further enhanced by IL-6. In Huh7 cells, DMOG
exposure completely abolished the induction of hepcidin by IL-6
(IL-6 3.861.5-fold, IL-6 plus DMOG 0.660.3-fold, n=4;
p,0.05; not shown). Compatible with the hypothesis that the
promoter region mediates the hepcidin response to IL-6, the
HAMP.prom luciferase reporter responded in a dose-dependent
fashion to IL-6, similar to the endogenous mRNA (Figure 5D).
Exposure to BMP-2, a further well characterized stimulus of
hepcidin gene expression [13,32], increased hepcidin promoter
activity, although high concentrations (50–100 ng/ml) were
required (Figure 5E). This effect was more pronounced in
serum-starved cells (0.4% FCS) than on a 10% FCS background,
which may be due to the contribution of BMPs in the FCS to
baseline hepcidin expression, in keeping with the observation that
serum deprivation leads to a rapid and marked decrease of
hepcidin mRNA levels as shown in Figure 2. Thus, the induction
of hepcidin by IL-6 and BMP-2 in the two hepatoma cell lines was
reproducible, dose-dependent and mediated by the proximal
promoter region, in agreement with previous studies
Figure 2. Response of hepcidin transcript levels to serum deprivation and protein kinase inhibition. (A) Serum withdrawal rapidly
decreased hepcidin transcript levels in Huh7 cells. (B) After 40 h of FCS reduction from 10% to 0.4%, hepcidin transcripts were hardly detectable by
RPA in HepG2 cells, whereas hypoxic IGFBP1 induction was not affected. Representative of three independent experiments. U6sn RNA served as
loading control. (C) Exposure of Huh7 cells to protein kinase inhibitors revealed that the pan kinase inhibitor staurosporine (stauro; 0.5 mM) and the
PI3 kinase inhibitor LY294002 (LY; 10 mM) reduced hepcidin expression similar to serum deprivation, whereas the p38 SAP kinase inhibitor SB202190
(SB; 10 mM) had no effect and the MEK1/2 inhibitor UO126 (1 mM) even increased HAMP/18S ratios. Data are results of qRT PCR analyses and given as
means of three independent experiments6SEM; *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0007875.g002
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by DMOG exposure and this depended on both the cell type and
the dose and timing of the two stimuli, suggesting that they employ
independent signal transduction pathways.
Transferrin Receptor 1 (TfR1/TFRC) Knock-Down Does
Not Reverse Hepcidin Down-Regulation in Hepatoma
Cells
The ubiquitously expressed TfR1 is believed to import
transferrin-bound iron (Fe2Tf) and interacts with HFE in the
absence of Fe2Tf, whereas TfR2 is suggested to act as a signal of
extracellular Fe2Tf availability resulting in hepcidin expression,
probably by activating the mitogen-activated protein kinases
ERK1/ERK2 and p38 [36]. While TfR1 is moderately inducible
by hypoxia and iron deficiency via HIF and iron regulatory
proteins (IRPs), TfR2 expression is not known to be regulated by
these stimuli. It thus appeared possible that upregulation of TfR1
expression by HIF or IRPs may lead to competition with TfR2 for
Fe2Tf and HFE and thus contribute to suppression of hepcidin
expression by reducing TfR2 signalling [37,38]. We tested this
hypothesis by siRNA-mediated knock-down of TfR1. Knock-
down was performed using three independent siRNAs in two
different laboratories and its efficiency was measured by RNase
protection assay, immunoblot and FACS analyses. Knock-down
amounted to about 90% at the mRNA and 70–85% (under
induced conditions) at the protein level (Figure 6A). The decrease
of hepcidin levels in the presence of hypoxia, iron chelation (Fe
2+
by DP and Fe
3+ by DFO) or chemical HIF stabilization by
DMOG exposure was not blunted by TfR1 depletion, but rather
enhanced (Figure 6B and data not shown). Thus, at least in vitro,
induction of TfR1 expression does not appear necessary for the
down-regulation of hepcidin transcription.
We then compared mRNA expression of TfR1 and TfR2 after
16 h exposure to hypoxia, DMOG and DP. As anticipated based
on its known regulation by HIF-1 and IRPs, TfR1 mRNA was
moderately increased by hypoxia, DMOG and DP after 16 h
(Figure 6C). Intriguingly TfR2 mRNA, which was less abundant
than TfR1 mRNA in both hepatoma cell lines, was moderately
increased by hypoxia, and reduced by DMOG and DP in Huh7
cells (Figure 6D, upper panel and bar graph). A similar pattern
was observed in HepG2 cells, although the increase by hypoxia
was somewhat less consistent than that seen in Huh7 cells
(Figure 6D, lower panel). Flow cytometry with a monoclonal
TfR2 antibody confirmed that in HepG2 cells the mRNA
regulation by DP and DMOG was accompanied by a reduction
of receptor protein on the cell surface to 66611% and 7964%
(n=3; p,0.05), respectively (Figure 7), whereas the increase by
hypoxia was not significant. TfR2 expression on Huh7 cells was
too low for flow cytometry.
Since this pattern of TfR2 regulation matched the modulation
of hepcidin transcripts, in particular the reduction by DMOG and
DP, regulation of TfR2 expression may contribute to the observed
responses of hepcidin expression in vitro.
Regulation of Endogenous BMP Expression Does Not
Underlie the Suppression of Hepcidin by DMOG and DP
Since hepcidin down-regulation by inhibitors of 2-OG-depen-
dent dioxygenases was neither mediated by HIF nor by
modulation of TfR1 expression, we further speculated that the
expression of BMPs may have been altered by the experimental
manipulations and may mediate hepcidin regulation. BMP-2, -4
and -6 have been shown to contribute to hepcidin expression in
HepG2 cells [32] and BMP6 was recently shown to be essential for
hepcidin expression in vivo [39,40]. We therefore determined
mRNA levels of these BMPs in hepatoma cells by reverse
transcriptase quantitative PCR. However, in contrast to TfR2
mRNA, BMP transcript levels did not correlate with hepcidin
expression. With the exception of BMP-2 and -6 in HepG2 cells,
all three BMPs were slightly up-regulated by hypoxia and
Figure 3. Suppression of hepcidin transcript levels is not mediated by HIF-1a or HIF-2a. (A) SiRNA-mediated knock-down of HIF-1a (1a)o r
HIF-2a (2a) did not attenuate the down-regulation of hepcidin mRNA levels in HepG2 cells after 16 h of stimulation; luciferase (luc) siRNA served as
negative control. (B) Immunoblots demonstrating the efficiency of HIF-1a and HIF-2a knock-down in HepG2 and Huh7 cells. (C) mRNA expression of
the established HIF target genes ANGPTL4 (HIF-1a target) and IGFBP1 (HIF-2a target in hepatoma cells) after HIF-a knock-down in HepG2 cells. (D)
Two independent HIF-1a siRNAs (1a,1 a*) reversed the hypoxic down-regulation of the negatively regulated HIF-1 target NUP98. (E) In Huh7 cells
hepcidin mRNA down-regulation by DMOG was not affected by HIF-a knock-down, whereas the decrease of NUP98 mRNA was reversed by HIF-1a
knock-down. Results shown are representative of at least three independent experiments.
doi:10.1371/journal.pone.0007875.g003
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(Figure 8). Thus, modulation of hepcidin expression by
endogenous BMPs does not seem to underlie the reduction of
hepcidin mRNA by DMOG and DP.
Short-Term Hypoxia Does Not Consistently Down-
Regulate Liver Hepcidin 1 mRNA Expression in Mice
To find out whether the reported down-regulation of liver
hepcidin mRNA levels in mice could be reproduced and inversely
Figure 4. The hypoxic response of the hepcidin promoter is cell type-specific and independent of HIF. (A) Sequence of the human
hepcidin promoter (acc. no. AD000684.1) with two putative HIF binding motifs which also conform to E-box/USF binding sites (yellow boxes, red
letters)andoneadditional HIF binding site(yellow);binding sites forp53(light blue), AP1 (blue-green),C/EBPa (green), STAT3 (pink), SMAD (grey)
are also marked; mRNA sequence (bold), translation start codon (ATG); underlined sequence represents region highly conserved between human
and murine hepcidin 1 gene. Lower sequence, two putative HREs were identified in the mouse hepcidin 1 gene about 2.1 kbp upstream to the
transcription start. These HIF binding sites do not conform to E-box/USF binding site consensus sequence. (B) A 617-bp human hepcidin
promoter construct (HAMP.prom) responded differently to hypoxia (hyp), DMOG and DP in HepG2 and Huh7 cells after 16 h of stimulation
(co=control). Data are means6SD of five (HepG2 cells) or three (Huh7 cells) independent experiments. (C) SiRNA knock-down of HIF-1a (1a)o r
HIF-2a (2a) did not reverse the down-regulation of promoter activity by DMOG in Huh7 cells; a 6xHRE luciferase reporter served as control. 3 luc
siRNAs served as negative control for the pGL2-based hepcidin promoter constructs and 2 luc siRNA as negative control for the pGL3 6xHRE;
deletion of the putative HREs in the HAMP promoter (HAMP.promDHRE) did not alter the response of the luciferase construct to DMOG nor did
HIF-a knock-down. (D) Deletion of putative HREs (HAMP.promDHRE) did not alter the response of the hepcidin promoter to DMOG, DP or hypoxia
in Huh7 cells. (E) Overexpression of a stable HIF-1a triple mutant (HIF-1aTM) tended to increase hepcidin promoter activity in comparison with
the empty vector control (pcDNA3). The 6xHRE reporter served as positive and the promoter-less pGL2basic vector as negative control,
respectively; HAMP promoter activities given in B–D are means of three independent experiments6SD. *p,0.05; **p,0.01 vs. unstimulated
control (co).
doi:10.1371/journal.pone.0007875.g004
Hepcidin Is Not a HIF Target
PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7875Figure 5. Transcriptional induction of hepcidin expression by IL-6 and BMP-2. (A) RNase protection assays demonstrating dose-dependent
induction of hepcidin mRNA by IL-6 in HepG2 and Huh7 cells. U6sn RNA served as loading control. (B) Quantification of hepcidin mRNA induction;
means6SD of three independent experiments; *p,0.05, **p,0.01 vs. unstimulated cells. (C) IL-6 blunted, but did not abrogate the down-regulation
of hepcidin mRNA levels by DMOG. IGFBP1 mRNA served as control for the hypoxic stimulation. (D) IL-6 activated the human hepcidin promoter
(HAMP.prom) in HepG2 and Huh7 cells. (E) Activation of the hepcidin promoter by BMP-2 (100 ng/ml) was mediated primarily by the proximal
promoter, since fusion of the 59adjacent CpG island to the proximal promoter (HAMP.prom.CpG) did not significantly alter the response to BMP-2.
The activation was more pronounced under serum-reduced conditions (0.4% FCS). D–E, data are means6SD of three independent experiments;
*p,0.05, **p,0.01 vs. unstimulated controls.
doi:10.1371/journal.pone.0007875.g005
Figure 6. TfR1 is not necessary for hepcidin down-regulation, but TfR2 and hepcidin expression correlate. (A) TfR1 mRNA and protein
levels were reduced by TfR1 siRNA transfection as determined by RNase protection assay (RPA) and immmunoblot; luciferase (luc) siRNA served as
negative control; a-tubulin (tub) was used as loading control for the immunoblot. DFO=desferrioxamine (100 mM). (B) In Huh7 cells hepcidin mRNA
down-regulation after 16 h of exposure to DMOG (DG), DP and hypoxia was not abrogated but rather enhanced by TfR1 knock-down;
co=unstimulated control cells. Data are representative of at least two independent experiments in either cell line. (C) TfR1 mRNA induction by
hypoxia, DMOG and DP in Huh7 cells, 40 mg total RNA were used per sample, n=3–4. (D) TfR2 mRNA regulation in Huh7 cells (upper panel) and
HepG2 cells (lower panel), 60 mg total RNA per sample; bar graph, quantification of TfR2 levels in Huh7 cells; n=4–6; *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0007875.g006
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normal (iron-rich) diet were exposed for 6–8 h to hypoxia (8% O2,
Figure 9A–B) or 0.1% carbon monoxide (CO, Figure 9B),
which leads to functional anemia and HIF activation. Surprisingly,
these conditions did not result in a consistent reduction of hepatic
hepcidin 1 mRNA expression (8 h hypoxia vs. normoxia p=0.2,
24 h hypoxia vs. normoxia p=0.4 in Mann Whitney test).
Hepcidin 1 mRNA levels were highly variable both under basal
and stimulated conditions (mean HAMP-1/U6sn ratios6SEM
normoxia 3669.3, 8 h hypoxia 18.964.5, 24 h hypoxia
24.765.7). Since female mice show higher baseline hepcidin
expression than males ([41]; Figure 9C), we used exclusively
female littermates for the experiments. Even under these
conditions, the response to hypoxia was variable and in the CO-
treated animals we observed up- rather than down-regulation of
hepatic hepcidin 1 mRNA. Mean HAMP-1/U6sn ratios6SEM
were 0.2860.022 in the CO-treated group vs. 0.1260.036 in the
control group (p,0.01 in Student’s t-test, p,0.05 in Mann
Whitney test; Figure 9B). The difference between the hypoxia-
treated group (0.1860.035) and the normoxic control group was
not significant (Student’s t-test and Mann Whitney test). To verify
that the experimental interventions were sufficient to up-regulate
HIF, expression of hepatic IGFBP1 and myocardial vascular
endothelial growth factor-A (VEGF) were measured. All animals
exposed to CO showed a marked induction of HIF target genes,
whereas the response to hypoxia was less pronounced and no more
detectable after 24 h hypoxia. One animal of the 8 h hypoxia
group quantitated in the bar graph in Figure 9A did not show liver
IGFBP1 induction, but also exhibited the lowest hepcidin 1
transcript level.
In a further experimental approach we used the chemical HIF
inducer N-oxalylglycine (OG), the water-soluble derivative of
DMOG, because chemical HIF induction is better tolerated
during prolonged exposure than hypoxia or CO. In vivo OG is
taken up by epithelial cells of the liver and kidney mediated by
different organic anion transporters. Because EPO is produced
by interstitial fibroblasts of the kidney, OG does not lead to
EPO induction which was confirmed by RT PCR in pilot
experiments (mean EPO/18S ratios6SEM of OG-treated mice:
0.3260.34, of hypoxic mice: 35.4622.2, of CO-exposed mice:
131.1661.2, normoxic mice=1; n=3 for each group). Five
male C57BL/6 mice were injected with 9.2 mg OG twice (24 h
OG +16 h OG), another five animals received at first OG and
after 24 h an injection with vehicle only (24 h OG +16 h Tris),
Figure 7. Effects of hypoxia, DMOG and DP on TfR2 protein expression in HepG2 cells. (A) FACS analysis of HepG2 cells with a TfR2 mouse
monoclonal antibody demonstrating TfR2 expression on HepG2 cells under baseline conditions in comparison with an isotype-matched negative
control antibody (co - TfR2). (B) After 16 h exposure to hypoxia a moderate induction was detected. After 16 h exposure to DMOG (C)o rD P( D) TfR2
protein expression was reduced. C–D, representative of three independent experiments; B, representative of two out of three experiments.
doi:10.1371/journal.pone.0007875.g007
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only. RNA was prepared from liver samples, and mRNA
expression of HAMP-1 and HIG2, a HIF target gene [22], was
determined by the use of quantitative RT PCR (Figure 9D). All
OG-treated animals showed a pronounced increase of HIG2
mRNA expression, indicative of HIF activation in the liver
(mean HIG2/18S ratios6SEM were 81.5616.2 in the 24 h
OG+16 h OG group compared with the control 1.060.18,
p,0.01; mean HIG2/18S ratios were 101.7624.4 in the 24 h
OG+16 h Tris group, p,0.05 vs. controls as analyzed by
Student’s t-test, p,0 . 0 5f o re i t h e rt r e a t m e n tg r o u pv s .c o n t r o l s
in Mann Whitney test). Comparable to the results obtained with
hypoxia and CO, HAMP-1 was slightly increased (n.s.), but not
decreased, by OG treatment. Mean HAMP-1/18S ratios6SEM
were 2.1560.63 for the 24 h OG +16 h OG group, 3.1560.74
for the 24 h OG +16 h Tris group and 160.31 for the control
group (n.s. in Student’s t-test, Mann Whitney test and one-way
ANOVA).
Although performed on a limited number of animals, these data
suggest that hepcidin regulation in vivo is complex and that, in the
short term, HIF activation in the liver is not sufficient to suppress
hepcidin.
Figure 8. Regulation of BMP-2, -4 and -6 mRNA expression in hepatoma cells. Quantitative RT PCR analysis of BMP-2 (A, D), BMP-4 (B, E)
and BMP-6 (C, F) mRNA expression in Huh7 (A–C) and HepG2 cells (D–F). Cells were exposed to 1% O2 (hyp), 100 mM DMOG or 100 mM DP for
16 hours. BMP mRNA levels were related to b-actin mRNA expression. Data given are means of two independent experiments and two RT PCRs per
experiment.
doi:10.1371/journal.pone.0007875.g008
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Hypoxia Does Not Reproducibly Lead to Hepcidin Down-
Regulation In Vitro and In Vivo
The aim of the present study was to determine the contribution
of HIF to the transcriptional regulation of hepcidin expression. In
contrast to previous studies [17,42,43], our results show that
hypoxia does not consistently suppress hepcidin expression in
human hepatoma cells or, after short-term hypoxia, carbon
monoxide exposure or N-oxalylglycine (OG) administration in
mice on a normal iron-rich diet. Moreover, experiments with
primary mouse hepatocytes also did not show a significant effect of
hypoxia (1.1960.4-fold induction vs. unstimulated controls, five
independent cell preparations, data not shown). In contrast, the
reduction of hepcidin mRNA levels by chemical HIF stabilizers, in
particular the iron chelator DP, was reproducible, but not
dependent on HIF-1a, HIF-2a, TfR1 induction or modulation
of BMP expression. In those experiments which showed a down-
regulation of hepcidin mRNA by hypoxia this was also not
dependent on HIF. The variability of the hypoxic hepcidin
Figure 9. Hepcidin 1 transcript levels are not consistently down-regulated by hypoxia or carbon monoxide in mice. (A) Mice exposed
to 8% O2 (hypoxia) for 8 h or 8 h 8% O2 followed by 16 h 10% O2 (=24 h) did not show significantly decreased liver hepcidin 1 (HAMP-1) mRNA
expression; no=normoxia. Representative RPA results (left panel) and quantification of HAMP-1 and IGFBP1 transcript levels in the total numbers of
animals used (right graphs). (B) 0.1% carbon monoxide (CO) for 6 h moderately increased hepcidin 1 transcript levels and markedly increased vascular
endothelial growth factor (VEGF) and IGFBP1 expression. The effect of hypoxia was again not significant. Representative RPA results and
quantification of HAMP-1 transcript levels in the total number of animals used. (C) Liver hepcidin mRNA levels of female (F) mice were higher than
those of males (M). (D) In an alternative approach, male C57BL/6 mice were injected with the HIF inducer N-oxylylglycine (OG) twice (24 h OG +16 h
OG; n=5) or once, followed by a vehicle injection (24 h OG +16 h Tris; n=5). The male control mice received vehicle only (24 h Tris +16 h Tris; n=3).
The left graph shows that in both treatment groups HAMP-1 mRNA levels were slightly, but not significantly increased 40 h after the first OG
injection. The right graph shows that HIF was activated by OG in the livers, because mRNA of the HIF target gene HIG2 was significantly induced
(indicated p values are Student’s t-test; p,0.05 for either OG group vs. control in Mann Whitney test).
doi:10.1371/journal.pone.0007875.g009
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of hypoxia on hepcidin expression.
Two previous studies confirmed the initially reported hepcidin
down-regulation by hypoxia [42,43], which may be due to
different experimental conditions, such as the duration of hypoxic
exposure (24 h vs. 16 h in our study) and the serum used for cell
culture. Prolonged hypoxia triggers a broad, predominantly HIF-
independent suppression of gene transcription, which may also
account for the down-regulation of hepcidin. In accordance with
our results, both studies demonstrated that the hypoxic down-
regulation was independent of HIF.
The results of the animal studies in the present report were
heterogeneous and did not show a consistent up- or down-
regulation of hepcidin by short-term hypoxia (6–24 h) in Balb/c
mice. Obviously, food intake and presumably also circadian
rhythms, as it was observed in humans [44], prevail over the effects
of hypoxia in mice. However, in two of three experiments we
found rather up- than downregulation of hepcidin expression by
hypoxia, carbon monoxide or the chemical HIF inducer OG
(although the increase only reached statistical significance in the
CO-treated group). In this respect, the results of a recent study that
showed HIF-2a-dependent expression of the intestinal epithelial
divalent metal transporter 1 (DMT1=NRAMP2) may be of
interest, because they suggest that hypoxia or chemical HIF
inducers could stimulate iron uptake by intestinal epithelial cells,
which may perhaps lead to elevated serum iron and hepcidin levels
[45].
Post-Transcriptional Mechanisms May Contribute to
Hepcidin mRNA Regulation
In HepG2 cells, DP exposure led to decreased hepcidin mRNA
levels, but activated the hepcidin promoter, suggesting that the
reduction of hepcidin mRNA expression is not due to transcrip-
tional suppression, but at least partially caused by post-transcrip-
tional mechanisms such as mRNA destabilization. Hepcidin
promoter activation by DP in HepG2 cells could be completely
prevented by HIF-1a knock-down, but was independent of the
putative HREs in the hepcidin promoter (data not shown),
suggesting that the marked HIF-1 activation by DP, which
reproducibly exceeds that by hypoxia and DMOG, induces a
factor which up-regulates hepcidin on the transcriptional level. At
present we have no explanation for this observation. BMP-2,-4,
and -6 expression patterns in HepG2 and Huh7 cells (Figure 8)
could not explain the difference between the two hepatoma cell
lines. Moreover, preliminary experiments showed that DP did not
induce IL-6 in hepatoma cells, which was a further candidate
mediator of hepcidin expression.
Serum Components Are Required for Hepcidin
Expression In Vitro and May Modulate Hepcidin
Regulation
One of the most striking results of the present study was the
rapid and marked decrease of hepcidin mRNA levels upon serum
withdrawal. This effect was not rescued by supplementation of
transferrin-bound iron, which indicates that other factors, e.g.
BMPs, IL-6 and/or growth factors are necessary for the high basal
hepcidin expression in HepG2 and Huh7 cells. A recent study
demonstrated association of TfR2 with lipid rafts and mitogen-
activated protein kinase signalling [36], which may hint at a
convergence of growth factor, cytokine and TfR2 signal
transduction pathways in hepcidin regulation and thus partially
explain the effects of serum components on hepcidin expression.
Presumably, not only the basal expression but also the hypoxic
regulation of hepcidin may be modulated by a balance between
hypoxia-regulated endogenous growth-factors and components of
the fetal calf serum, since a change of the batch of serum used for
cell culture also modulated the hypoxic hepcidin response and
caused the high variability of the hypoxic hepcidin response as
demonstrated in Figure 1. Identification of which components of
fetal calf serum are necessary to maintain hepcidin expression,
although beyond the scope of this study, may provide novel targets
for future therapies able to modulate hepcidin levels in human
disease. In the present study, we show by the use of protein kinase
inhibitors that PI3 kinase activity is required for basal hepcidin
expression in Huh7 cells, whereas inhibition of the MAP kinase
pathway did not decrease, but rather increased hepcidin mRNA
levels in Huh7 and HepG2 cells.
The Regulation of TfR2 Expression Parallels Hepcidin
Expression in Hepatoma Cells
A further novel finding of the present study was that, in contrast
to BMPs, TfR2 expression was regulated in a pattern that matched
hepcidin regulation: hypoxia slightly increased, whereas DP and
DMOG decreased, TfR2 expression. TfR2 mutations have been
reported to underlie hereditary hemochromatosis indicating a
pivotal role for TfR2 in the transcriptional regulation of hepcidin
(for review see [12]). Recently, Gao and co-workers demonstrated
that in the presence of transferrin-bound iron (Fe2Tf), TfR1 is
released from its interaction with HFE and replaced by the TfR2-
Fe2Tf complex, though at an alternative binding domain of HFE
[38]. Thus, HFE may transcriptionally activate hepcidin through
TfR2 signaling, emphasizing the functional significance of TfR2 in
hepcidin expression. The study also showed that HFE expression
is low in HepG2 cells and overexpression is required to elicit clear
Fe2Tf effects in HepG2 cells, which may explain the rather
moderate effects of the experimental interventions observed in the
present study.
Due to these limitations of cell culture models, we also cannot
rule out that in vivo modulation of TfR1 expression by IRPs and/or
HIF may regulate hepcidin expression.
Determinants of Hepcidin Expression In Vivo: A Paradigm
Shift?
Previous reports demonstrated that the decrease of hepcidin
expression by experimentally induced anemia in animals is
dependent on erythropoiesis, since it could be abolished or
blunted by inhibitors of erythropoiesis such as irradiation,
carboplatin, doxorubicin or EPO-blocking antibodies [46,47].
These results suggested that hepcidin may respond to a signal
arising from the erythropoietic activity itself and showed that
anemia and tissue hypoxia per se were not sufficient to suppress
hepcidin. Although liver-specific HIF-1a and VHL knock-out
models rather suggested direct effects of HIF on hepcidin
expression [21], the experiments presented did not exclude that
the stimulation of erythropoiesis was the underlying cause of the
observed effect on hepcidin. Growth differentiation factor 15 and
BMP-6 have recently been implicated in hepcidin regulation in
mice [14,48,49]. It is therefore conceivable that the balance and
competition between factors of the transforming growth factor
family, secreted by the expanding erythron and the liver may be
critical in the transcriptional regulation of hepcidin.
However, a recent study in chronic kidney disease (CKD)
patients, based on a novel immunoassay detecting the functional
25-amino acid hepcidin peptide, rather suggested that erythropoi-
esis may be the signal for hepcidin suppression [44]. More
recently, erythropoietin administration to healthy humans (which
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result in profound and prolonged suppression of circulating
hepcidin which could not be attributed to changes in circulating
iron or GDF-15 [50]. This indicates that, also in humans, neither
hypoxia nor anemia are required for the suppression of hepcidin
by erythropoiesis and challenges the idea that erythropoietin
induction and hepcidin inhibition are parallel effects of HIF
activation. While there is some evidence that erythropoietin may
directly suppress hepcidin production in HepG2 cells in culture
[51], the two collaborating groups of this manuscript could not
reproduce these experiments (data not shown) and it seems more
likely that a circulating factor released by the bone marrow is able
to modulate hepcidin expression, not least because bone marrow
ablation prevents suppression of hepcidin following erythropoietin
administration in mice [47].
In keeping with the known limitations of cell culture models, our
data show that hepcidin is not a direct negative target of HIF, but
its expression can be modulated by a multitude of extrinsic factors
and cell-autonomous regulatory pathways, some of which may be
subject to regulation by HIF. While identification and pharma-
cological targeting of these factors may provide novel clinical
therapies for the treatment of hemochromatosis or anemia of
chronic disease (ACD), the pharmacological HIF inducers which
are currently in clinical trials may exert suppressive effects on
hepcidin as a consequence of the induction of erythropoiesis by
increasing erythropoietin production and would therefore not be
illogical treatments for ACD. Whether they are superior to EPO
therapy in the treatment of ACD remains to be shown.
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